Nature Medicine, Published online: 16 April 2026; doi:10.1038/s41591-026-04340-7 In this phase 1/2 trial, patients with Ewing sarcoma received trabectedin and low-dose irinotecan at concentrations known to inhibit the activity of the transcription factor EWS::FLI1, leading to encouraging clinical response rates.
Nature Medicine published a clinical update in Research Highlights on 16 Apr 2026. The item focuses on Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial. Open the detail page to review the full original feed content.